Skip to content

To assess the safety and effectiveness of vortioxeTine and escitalopram with clonazepam in anxious depressive patients

A real world assessment for Safety and effectiveness of VORtioxeTine and Escitalopram with Clonazepam in anXious depression - VORTEX STUDY

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068554
Enrollment
200
Registered
2024-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F418- Other specified anxiety disorders

Interventions

Intervention1: Nill: Nill Intervention2: Escitalopram: 5mg, 10mg, 20mg (FELIZ-S) Vortioxetine: 5mg, 10 mg, 20mg (VOXIGAIN/TORVOX) Clonazepam: 0.5 mg (CLONOTRIL): Dosage Form: tablets Route of administ

Sponsors

TORRENT PHARMA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or female patients 18 to 65 years with DSM-V defined MDD with anxious depression. Treatment naïve patients or known cases already on VOR or ESC not exceeding two weeks of active treatment. ? Patients with MADRS score is greater than 20 and HAM-A score is greater than 25. Patient with normal physical examination clinical laboratory and ECG findings (as per physicians discretion) Patients who are willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: Patient aged less than 18 years and more than 65 years will be excluded. Patient with MADRS less than 19 and HAM-A less than 24. Patients requiring second generation antipsychotics or lithium. Patient in which the use of benzodiazepine is contraindicated. Patient with other conditions who do not fit into the criteria of the study as per the protocol. Patient with known hypersensitivity to Vortioxetine, Escitalopram, Clonazepam or any excipients. Patients who are not willing to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to 2 and 6 week. Change in Hamilton Anxiety Rating Scale for Anxiety (HAM –A) total scores from baseline to 2 and 6 week.Timepoint: 2 and 6 weeks.

Secondary

MeasureTime frame
Clinical Global Impression for Efficacy Index (CGI-EI) at 2 and 6 Week Treatment Emergent Adverse event (TEAE) assessment at every scheduled visit Change in Sexual function or ASEX score from baseline to 2 week and 6 weekTimepoint: 2 and 6 weeks

Countries

India

Contacts

Public ContactDr Krishnaprasad K

Asha Hospital

prasad40@gmail.com9985900005

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026